Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Journal article published in 2016 by
S. Barco 
,
M. Lankeit,
H. Binder,
S. Schellong,
M. Christ,
J. Beyer Westendorf,
D. Duerschmied,
R. Bauersachs,
K. Empen,
M. Held,
M. Schwaiblmair,
C. Fonseca,
D. Jiménez,
C. Becattini,
K. Quitzau
and other authors.
,
M. Lankeit,
H. Binder,
S. Schellong,
M. Christ,
J. Beyer Westendorf,
D. Duerschmied,
R. Bauersachs,
K. Empen,
M. Held,
M. Schwaiblmair,
C. Fonseca,
D. Jiménez,
C. Becattini,
K. Quitzau
and other authors.
